AT 13387

Known as: AT-13387, AT13387 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2016
024620102016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Emergence of clinical resistance to BRAF inhibitors, alone or in combination with MEK inhibitors, limits clinical responses in… (More)
Is this relevant?
2014
2014
Purpose: AT13387 is a potent second-generation, fragmentderived HSP90 inhibitor. This phase I study investigated the maximum… (More)
  • table 1
  • table 4
  • figure 1
  • figure 2
  • table 5
Is this relevant?
2013
2013
Nasopharyngeal carcinoma (NPC) is an epithelial malignancy strongly associated with Epstein-Barr virus (EBV). AT13387 is a novel… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
A ubiquitously expressed chaperone, heat shock protein 90 (HSP90) is of considerable interest as an oncology target because tumor… (More)
Is this relevant?
2012
2012
The epidermal growth factor receptor (EGFR) has been targeted for inhibition using tyrosine kinase inhibitors and monoclonal… (More)
Is this relevant?
2012
2012
The majority of gastrointestinal stromal tumors (GIST) are characterized by activating mutations of KIT, an HSP90 client protein… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
AT13387, a non-geldanamycin inhibitor of heat-shock protein 90 (HSP90), was tested against the PPTP in vitro panel (1.0 nM to 10… (More)
Is this relevant?
2012
2012
The synthesis of C-5-substituted resorcinol amide AT13387, a known Hsp90 inhibitor currently in clinical trials, is reported… (More)
Is this relevant?
2011
2011
Hsp90 is involved in correcting, folding, maturation and activation of a diverse array of client proteins; it has also been… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2010
2010
Inhibitors of the molecular chaperone heat shock protein 90 (Hsp90) are currently generating significant interest in clinical… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?